Holen Sie sich die Stockscreener-App
22.32
3.00%
-0.69
Schlusskurs vom Vortag:
$23.01
Offen:
$22.91
24-Stunden-Volumen:
1.87M
Relative Volume:
1.10
Marktkapitalisierung:
$4.12B
Einnahmen:
$797.73M
Nettoeinkommen (Verlust:
$-325.77M
KGV:
-12.59
EPS:
-1.7725
Netto-Cashflow:
$-332.79M
1W Leistung:
-20.65%
1M Leistung:
-28.40%
6M Leistung:
-41.12%
1J Leistung:
-37.11%
1-Tages-Spanne:
$22.27
$23.14
1-Wochen-Bereich:
$22.27
$27.87
52-Wochen-Spanne:
$22.27
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Firmenname
Legend Biotech Corp Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie LEGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
22.32 | 4.25B | 797.73M | -325.77M | -332.79M | -1.7725 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-06-17 | Eingeleitet | Truist | Buy |
| 2024-05-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Buy |
| 2024-04-17 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | Raymond James | Outperform |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-11-06 | Eingeleitet | Goldman | Buy |
| 2023-05-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-05-22 | Eingeleitet | Daiwa Securities | Buy |
| 2023-03-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-11-02 | Eingeleitet | Evercore ISI | Outperform |
| 2022-11-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-03-15 | Eingeleitet | Barclays | Overweight |
| 2022-01-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-07-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Legend Biotech Corp Adr Aktie (LEGN) Neueste Nachrichten
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Braidwell LP - MarketBeat
Nothing is Better Than Harrow Inc (HROW) stock at the moment - Setenews
Ready to Jump After Recent Trade: Venture Global Inc (VG) - setenews.com
Stempoint Capital LP Takes $9.59 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock remains Outperform at RBC despite competitive threats - Investing.com
Federated Hermes Inc. Has $37.75 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at $25.66 By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $25.66 - Investing.com
Legend Biotech stock maintains Outperform rating at RBC on Carvykti efficacy - Investing.com
Legend Biotech Corporation Sponsored ADR $LEGN Shares Purchased by New York State Common Retirement Fund - MarketBeat
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma - GlobeNewswire Inc.
Schroder Investment Management Group Has $6.74 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
A Look at Dutch Bros Inc (BROS) Shares in the Recent Past Indicates Growth - setenews.com
Decheng Capital LLC Sells 80,000 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Hsbc Holdings PLC Has $16.90 Million Stake in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Free cash flow per share of Legend Biotech Corp. Sponsored ADR – BER:9LB - TradingView
Advisors Asset Management Inc. Acquires 3,895 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
SG Americas Securities LLC Has $263,000 Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Ensign Peak Advisors Inc - Defense World
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Geode Capital Management LLC - Defense World
Franklin Resources Inc. Purchases 27,148 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corporation Sponsored ADR $LEGN Position Trimmed by Handelsbanken Fonder AB - MarketBeat
BLI Banque de Luxembourg Investments Has $10.57 Million Position in Yum China $YUMC - Defense World
Popular, Inc. $BPOP Shares Purchased by Franklin Resources Inc. - Defense World
Franklin Resources Inc. Purchases 72,502 Shares of American Healthcare REIT, Inc. $AHR - Defense World
Ensign Peak Advisors Inc Boosts Holdings in Medical Properties Trust, Inc. $MPW - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Black Cypress Capital Management LLC Increases Stock Holdings in SLB Limited $SLB - Defense World
Creative Planning Grows Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
OPTIMAS CAPITAL Ltd Takes $1.54 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns - Finviz
Legend Biotech stock hits 52-week low at $27.27 - Investing.com
Legend Biotech Corporation Sponsored ADR $LEGN Shares Bought by CenterBook Partners LP - MarketBeat
Artisan Partners Limited Partnership Buys 990,500 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by KBC Group NV - MarketBeat
FY2025 EPS Estimates for Legend Biotech Reduced by Analyst - MarketBeat
Take off with Legend Biotech Corp ADR (LEGN): Get ready for trading - Setenews
Company News for Nov 13, 2025 - sharewise.com
Earnings call transcript: Legend Biotech’s Q3 2025 results miss forecasts By Investing.com - Investing.com Philippines
Earnings call transcript: Legend Biotech’s Q3 2025 results miss forecasts - Investing.com
Barrick Mining (B) Projected to Post Quarterly Earnings on Monday - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: SharkNinja Inc (SN) - setenews.com
The growth track for Legend Biotech Corp ADR (LEGN) has changed recently - Setenews
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A new trading data show Legence Corp (LGN) is showing positive returns. - Setenews
iA Global Asset Management Inc. Lowers Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Reduces Holdings in Essential Properties Realty Trust, Inc. $EPRT - Defense World
Sumitomo Mitsui Trust Group Inc. Sells 11,157 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Clean Harbors (NYSE:CLH) Shares Gap Down on Disappointing Earnings - Defense World
Finanzdaten der Legend Biotech Corp Adr-Aktie (LEGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):